Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -56.15% | -44.59% | -34.11% | -33.71% | -45.27% |
| Total Depreciation and Amortization | 27.36% | 95.15% | 200.76% | 182.05% | 168.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.50% | 55.24% | 18.60% | 39.98% | 73.43% |
| Change in Net Operating Assets | -29.59% | -454.27% | -103.71% | -144.33% | 311.93% |
| Cash from Operations | -80.19% | -67.35% | -67.92% | -51.97% | -4.17% |
| Capital Expenditure | -235.29% | 6.98% | -10.05% | 84.91% | -302.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 178.11% | -5,262.83% | -526.42% | 111.13% | -266.34% |
| Cash from Investing | 170.75% | -27,919.09% | -520.89% | 110.66% | -270.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.81% | -98.92% | 1,408.44% | -83.63% | -64.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -3,337.65% | 92.99% | 912.86% |
| Cash from Financing | -6.22% | -98.87% | 1,360.88% | -83.03% | -40.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.44% | -149.84% | 40.02% | -85.37% | -5,613.71% |